Company news

ExpreS2ion Biotech Holding AB news in 2026

ExpreS2ion Biotech Holding AB's news releases, calls and decks from 2026, newest first.

View company

ExpreS2ion Biotech Obtains Commitment for Warrant Program TO 13 and enters into SEK 50 Million Put Option Agreement with lead investor Alumni Capital

September 14, 2026

ExpreS2ion Announces Financial Results for the Second Quarter and First Half of 2026

August 20, 2026

ExpreS2ion annual report for 2025 published

June 4, 2026

ExpreS2ion Announces Financial Results for the First Quarter of 2026

May 28, 2026

ExpreS2ion resolves on a set-off issue to one guarantor in connection with completed rights issue

May 11, 2026

ExpreS2ion Biotech: Rights issue outcome – SEK31.8m raised

May 5, 2026

ExpreS2ion announces final outcome of its rights issue of units

May 4, 2026

ExpreS2ion Biotech advances breast cancer project with rights issue of SEK 53 million

April 20, 2026

ExpreS2ion featured in BioStock investor presentation as subscription period opens in SEK 53 million rights issue

April 16, 2026

ExpreS2ion publishes prospectus in connection with SEK 53 million rights issue to complete Phase I and support partnering activities

April 14, 2026

The Board of Directors of ExpreS2ion has resolved on a rights issue of units of approximately SEK 53 million, primarily to advance its lead cancer program, and publishes terms for the rights issue

April 7, 2026

ExpreS2ion Announces Financial Results for the Full-Year and Fourth Quarter of 2025

February 19, 2026

Calls in 2026

Decks in 2026